Elamipretide (50mg)

Elamipretide constitutes a small, aromatic peptide recognized for its remarkable ability to effortlessly traverse cell and organelle membranes. Its proposed mechanism involves interference with the generation of reactive oxygen species (ROS or free radicals) while fostering cellular energy production. This is achieved by stabilizing the enzyme cardiolipin situated within mitochondria, a vital element of the inner mitochondrial membrane essential for the electron transport chain—an integral machinery responsible for producing the majority of cellular energy.

Dysfunction in cardiolipin has been implicated in the pathology of various diseases, spanning Alzheimer’s disease, Parkinson’s disease, nonalcoholic fatty liver disease, diabetes, heart failure, HIV, cancer, chronic fatigue syndrome, among others. Furthermore, cardiolipin’s role is pivotal in mitochondrial myopathy—a group of neuromuscular disorders resulting from mitochondrial damage. This condition encompasses a spectrum from muscle weakness and exercise intolerance to heart failure, seizures, and dementia.

Remarkably, Elamipretide holds the distinction of being the initial peptide to undergo clinical trials as a potential treatment for mitochondrial myopathy.